Editas Medicine (NASDAQ: EDIT)announced first-quarter 2018 results on Thursday after the market closed, detailing expanded partnerships, progress for its important LCA10 drug candidate, and a number of other intriguing updates for the broader business.
Editas Medicine Starts a "Transformative" Year on a High Note
Понравилась статья? Подпишитесь на канал, чтобы быть в курсе самых интересных материалов
Подписаться